Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Frequency Therapeutics Inc (NQ: FREQ ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Nov 3, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Frequency Therapeutics Inc < Previous 1 2 3 4 Next > FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ October 06, 2023 From Kahn Swick & Foti, LLC Via Business Wire Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results August 10, 2023 From Frequency Therapeutics, Inc. Via Business Wire FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ July 21, 2023 From Kahn Swick & Foti, LLC Via Business Wire FREQ Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Frequency Therapeutics, Inc. Is Fair to Shareholders July 14, 2023 From Halper Sadeh LLC Via Business Wire Korro Bio and Frequency Therapeutics Announce Merger Agreement July 14, 2023 From Korro Bio, Inc. Via Business Wire Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results May 12, 2023 From Frequency Therapeutics, Inc. Via Business Wire Why Did Bullfrog AI Stock Jump More Than 50%? April 05, 2023 Trading volume and share price for BFRG took significant leaps forward on news the digital biopharmaceutical company will partner with Johns Hopkins University. Via MarketBeat Topics Artificial Intelligence Initial Public Offering Exposures Artificial Intelligence Securities Market Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results March 10, 2023 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics to Participate at Upcoming March Investor Conferences February 27, 2023 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss February 13, 2023 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program December 19, 2022 From Frequency Therapeutics Via Business Wire Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss December 15, 2022 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results November 17, 2022 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results November 08, 2022 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss October 12, 2022 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics to Participate in September Investor and Medical Conferences August 30, 2022 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results August 09, 2022 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference May 18, 2022 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results May 04, 2022 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference April 22, 2022 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results March 15, 2022 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences February 28, 2022 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference January 04, 2022 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise December 09, 2021 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results November 15, 2021 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis November 09, 2021 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program October 27, 2021 From Frequency Therapeutics, Inc. Via Business Wire Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint October 21, 2021 From Frequency Therapeutics, Inc. Via Business Wire NASDAQ:FREQ Long Term Shareholder Notice: Investigation of Potential Wrongdoing at Frequency Therapeutics, Inc. September 29, 2021 San Diego, CA -- (SBWIRE) -- 09/29/2021 -- Certain directors of Frequency Therapeutics, Inc. are under investigation over possible breaches of fiduciary duties. Via SBWire Topics Lawsuit Exposures Financial Legal Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points September 22, 2021 From Frequency Therapeutics, Inc. Via Business Wire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.